Renalyte is developing a fully implantable Renal Assist Device (RAD) designed to provide continuous, 24/7 blood filtration as an alternative to traditional hemodialysis.

The system utilizes a Safe-by-Design architecture, leveraging a venous-only approach to blood access.

This methodology eliminates the complications associated with arterial-venous pressure gradients, lowering the surgical barrier for implantation and reducing long-term clinical risk.By automating fluid and toxin removal internally, the technology seeks to shift the paradigm of End-Stage Renal Disease (ESRD) care from intermittent, clinic-based treatment to a continuous, internal solution.

Renalyte’s Pragmatic Disruption model addresses the US Medicare mandate for efficient, value-based kidney care.

With two US patents granted, the company is currently advancing through pre-clinical milestones to validate Proof of Concept (POC) and system durability.